Corey E. Hayford

The paper identifies DCN1 as a therapeutic target for beta-hemoglobinopathies by showing its inhibition increases fetal hemoglobin through selective chromatin changes without cytotoxicity.

The paper introduces PIPseq V, a single-cell RNA sequencing method using Intrinsic Molecular Identifiers (IMIs) to improve transcript counting and reduce biases compared to traditional UMIs.

The paper introduces PIP-seq, a microfluidics-free method for single-cell RNA sequencing that enables high-throughput, scalable, and flexible processing of samples.

The paper identifies heterogeneous drug-tolerant persisters (DTPs) as population-level states with distinct division and death rates, showing increased ferroptosis susceptibility.

This study disentangles genetic, epigenetic, and stochastic factors contributing to drug-response variability in an in vitro tumor heterogeneity model using PC9 cell lines.

The paper identifies a drug-tolerant metabolic state in melanoma cells that reduces both glycolysis and oxidative phosphorylation, supporting survival but limiting growth.

The paper shows that increased antioxidant capacity in BRAF-mutated melanoma cells reduces sensitivity to BRAF inhibitors and suggests targeting redox pathways could improve treatment outcomes.